Dupilumab efficacy in patients with GINA-defined type 2 asthma: TRAVERSE Source: Virtual Congress 2021 – Pearls in immunology, outcome studies and clinical trials in asthma, alpha-1 antitrypsin deficiency and COPD Year: 2021
Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma Source: Eur Respir J, 52 (4) 1800936; 10.1183/13993003.00936-2018 Year: 2018
Effect of patients‘ characteristics and asthma management on control Source: Eur Respir J 2005; 26: Suppl. 49, 381s Year: 2005
The ARIETTA study: baseline demographics in a real-world setting in patients with severe asthma Source: International Congress 2017 – Bronchial asthma management Year: 2017
Patient baseline variables predict future asthma control status and risk of exacerbations Source: Annual Congress 2010 - Management of airway disease Year: 2010
Baseline characteristics of severe asthma patients initiating biologic treatment worldwide Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021
Effect of dupilumab on patient-reported sleep outcomes in patients with severe asthma Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021
Relationship between baseline rescue medication use and reductions in COPD exacerbation rates: a subgroup analysis of the ETHOS trial Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021
Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Influence of personal characteristics of patients with bronchial asthma on their medication adherence Source: International Congress 2018 – Airway disease: recent discoveries Year: 2018
Real life experience with omalizumab and mepolizumab in severe asthma : do patient baseline features preclude effectiveness comparison ? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Relationship between omalizumab efficacy and baseline allergen profile impacts patient-reported outcomes in allergic asthma Source: International Congress 2018 – Tests and trends in asthma Year: 2018
MARTE: an observational study on clinical and sociodemographic characteristics of asthmatic patients receiving maintenance and rescue treatment in Spain Source: International Congress 2018 – Asthma: clinical screening tools Year: 2018
Baseline characteristics of patients with frequent exacerbations in the POET-COPDÔ trial Source: Annual Congress 2011 - Diagnosis and predictors of COPD exacerbation Year: 2011
Effect of ICS on glycaemic control in patients with COPD and comorbid type 2 diabetes: Historical case-matched cohort study Source: International Congress 2016 – Managing multimorbidity and lifestyle change in primary care Year: 2016
Impact of add-on medications on patient‘s satisfaction in patients with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 273s Year: 2005
Engagement with an asthma app to monitor medication adherence and its association with patients’ characteristics Source: Virtual Congress 2021 – Remote monitoring of respiratory patients Year: 2021
COPD eDiary compliance: Comparison of age, symptom score, duration in clinical trial and country of origin Source: Annual Congress 2010 - Risk factors, prevalence and consequences of COPD Year: 2010
Symptom pattern and treatment for people non-compliant with asthma medication Source: Annual Congress 2005 - Allergic rhinitis and asthma in primary care Year: 2005
A long-term (2 years) efficacy and safety study of doxofylline in the treatment of asthma Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019